Prevalence and clinical outcomes of dystrophin-associated dilated cardiomyopathy without severe skeletal myopathy

M.A. Restrepo-Cordoba, K. Wahbi, A.R. Florian, J. Jimenez-Jaimez, L. Politano, M. Arad, V. Climent-Paya, A. Garcia-Alvarez, R.B. Hansen, J.M. Larranaga-Moreira, M. Kubanek, L.R. Lopes, A. Ros, R. Jurcut, T.B. Rasmussen, L. Ruiz-Guerrero, R. Pribe-Wolferts, J. Palomino-Doza, Z. Bilinska, J.F. Rodriguez-PalomaresR.L.E. Van Loon, M.T.B. Elorz, G. Quarta, M.R. Inarritu, J.A.J. Verdonschot, T. Stojkovic, Z. Shomanova, F. Bermudez-Jimenez, A. Palladino, D. Freimark, M.I. Garcia-alvarez, P. Jorda, F. Dominguez, J.P. Ochoa, F. Girolami, R. Brugada, B. Meder, R. Barriales-Villa, J. Mogensen, P. Laforet, A. Yilmaz, P. Elliott, P. Garcia-Pavia*, European Genetic Cardiomyopathies Initiative Investigators

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Web of Science)
Original languageEnglish
Pages (from-to)1276-1286
Number of pages11
JournalEuropean journal of heart failure
Volume23
Issue number8
DOIs
Publication statusPublished - 1 Aug 2021

Keywords

  • Dystrophin
  • DMD
  • Dilated cardiomyopathy
  • Heart failure
  • Myopathy
  • RISK STRATIFICATION
  • DUCHENNE
  • MANAGEMENT
  • DEATH

Cite this